Abstract

Viral vectors are increasingly used as delivery means to induce a specific immunity in humans and animals. However, they also impact the immune system, and it depends on the given context whether this is beneficial or not. The attenuated vaccinia virus strain modified vaccinia virus Ankara (MVA) has been used as a viral vector in clinical studies intended to treat and prevent cancer and infectious diseases. The adjuvant property of MVA is thought to be due to its capability to stimulate innate immunity. Here, we confirmed that MVA induces interleukin-8 (IL-8), and this chemokine was upregulated significantly more in monocytes and HLA-DRbright dendritic cells (DCs) of HIV-infected patients on combined antiretroviral therapy (ART) than in cells of healthy persons. The effect of MVA on cell surface receptors is mostly unknown. Using mass cytometry profiling, we investigated the expression of 17 cell surface receptors in leukocytes after ex vivo infection of human whole-blood samples with MVA. We found that MVA downregulates most of the characteristic cell surface markers in particular types of leukocytes. In contrast, C-X-C motif chemokine receptor 4 (CXCR4) was significantly upregulated in each leukocyte type of healthy persons. Additionally, we detected a relative higher cell surface expression of the HIV-1 co-receptors C-C motif chemokine receptor 5 (CCR5) and CXCR4 in leukocytes of HIV-ART patients than in healthy persons. Importantly, we showed that MVA infection significantly downregulated CCR5 in CD4+ T cells, CD8+ T cells, B cells, and three different DC populations. CD86, a costimulatory molecule for T cells, was significantly upregulated in HLA-DRbright DCs after MVA infection of whole blood from HIV-ART patients. However, MVA was unable to downregulate cell surface expression of CD11b and CD32 in monocytes and neutrophils of HIV-ART patients to the same extent as in monocytes and neutrophils of healthy persons. In summary, MVA modulates the expression of many different kinds of cell surface receptors in leukocytes, which can vary in cells originating from persons previously infected with other pathogens.

Highlights

  • Protection of humans against infectious diseases by vaccination is considered as one of the greatest successes in the history of medicine

  • It is well established that modified vaccinia virus Ankara (MVA) induces cytokine production [24,25,26], but it is mostly unknown whether cells of immunocompromised persons including those of HV1-infected patients respond to this viral vector

  • We found that ex vivo infection of whole blood with MVA significantly induced the production of IL-8, CCL2, and CCL4 in monocytes and HLA-DRhigh dendritic cells (DCs) of HIV-antiretroviral therapy (ART) patients and healthy persons (Figures 1A,B)

Read more

Summary

Introduction

Protection of humans against infectious diseases by vaccination is considered as one of the greatest successes in the history of medicine. Vaccinia virus (VACV) has been successfully used to vaccinate against smallpox, but it can cause severe side effects [1, 2]. As an effort to attenuate VACV in a way that increases its safety while keeping its immunogenic potential, chorioallantois vaccinia virus Ankara (CVA) was passaged multiple times in chicken embryo fibroblasts (CEFs). This yielded a modified VACV strain, which does not replicate in primary human cells [3]. Vaccination of persons with the modified vaccinia virus Ankara (MVA) was well tolerated in more than 120,000 persons [4], and recently, the safety and efficacy of MVA were confirmed in a phase 3 clinical trial designed for the usage of MVA against smallpox [5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call